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Abstract
The leukemia-associated fusion protein MN1-TEL combines the transcription-activating domains of MN1 with the DNA-
binding domain of the transcriptional repressor TEL. Quantitative photobleaching experiments revealed that ,20% of GFP-
tagged MN1 and TEL is transiently immobilised, likely due to indirect or direct DNA binding, since transcription inhibition
abolished immobilisation. Interestingly,,50% of the MN1-TEL fusion protein was immobile with much longer binding times
than unfused MN1 and TEL. MN1-TEL immobilisation was not observed when the TEL DNA-binding domain was disrupted,
suggesting that MN1-TEL stably occupies TEL recognition sequences, preventing binding of factors required for proper
transcription regulation, which may contribute to leukemogenesis.
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Introduction
The translocation t(12;22) fuses the MN1 and TEL genes and
leads to AML. The product of this rare fusion consists of 1259
amino acids (aa) encoded by the firstMN1 exon fused to aa 55-452
of TEL [1].
TEL is a repressor from the ETS family of transcription factors,
most of which are, unlike TEL, transcriptional activators [2]. The
ETS family consists of over 40 genes and is defined by its
conserved DNA-binding domain (DBD). TEL belongs to a subset
of ETS proteins that contain a second conserved N-terminal helix-
loop-helix (HLH) dimerization domain. Dimerization is important
for activation of partner kinases such as ABL1 in the TEL-ABL1
fusion protein [3]. TEL is a partner in many leukemic fusion
proteins, where its HLH and sometimes also the central domains
are fused. MN1-TEL is considered the prototype of leukemia-
associated fusions to which TEL contributes its DBD [4]. The
combination of the transactivating domain (TAD) of MN1 with
the DBD of TEL is thought to perturb transcriptional repression
normally executed by TEL.
MN1 is a protein of 1319 aa and contains an N-terminal
transcription-activating domain (TAD). MN1 functions as a tran-
scription cofactor, both inhibitory and stimulatory for retinoic acid
receptor/retinoic-X-receptor (RAR-RXR) and vitamin D/RXR-
mediated transcription [5,6,7,8]. MN1, acting as a co-activator,
was shown to bind transcription co-activators such as p300 and
SRC3 and to synergistically stimulate the transcriptional activity of
the RAR/RXR heterodimer. High MN1 expression was shown to
be a predictor of poor clinical outcome in AML patients with
a normal karyotype [9]. Mice receiving transplants of MN1-
overexpressing bone marrow rapidly developed myeloproliferative
disease [6,10]. When co-expressed with the inv(16) Cbfb-SMMHC
fusion gene full blown leukemia developed, resembling human
leukemia caused by this fusion gene which is always accompanied
by high expression of the MN1 gene.
The fusion product MN1-TEL inhibits RAR/RXR-mediated
transcription and acts as a dominant-negative mutant of MN1.
Compared to MN1, the TAD in MN1-TEL is poorly stimulated
by p160 and p300/CBP, indicating that the block of RAR/RXR-
mediated transcription by MN1-TEL is caused by dysfunctioning
of the TAD, rather than by recruitment of co-repressors [11].
Forced expression of MN1-TEL in mice causes leukemias and
lymphoid tumors [12,13,14]. We hypothesized that the leukemo-
genic potential of MN1-TEL can be attributed to two distinct
characteristics. First, MN1-TEL can stimulate TEL-responsive
genes by binding to ETS elements and thereby interfere with the
repressive effect of TEL, and secondly MN1-TEL can act as
a dominant-negative mutant of MN1, as it efficiently represses
RAR/RXR-mediated transcription even in the presence of MN1.
One of the methods to examine the behavior of transcription
factors such as MN1, TEL and MN1-TEL in living cells is
fluorescence recovery after photobleaching (FRAP). This method
gives insight into the mobility of fluorescently-tagged proteins
which provides quantitative information about protein-chromatin
interactions since binding to chromatin leads to immobilisation
[15]. In the present work we investigated the mobility of MN1,
TEL and MN1-TEL proteins to gain more insight in transcription
deregulation by MN1-TEL. Our results suggest that a large
fraction of the MN1-TEL protein is tightly bound to DNA
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Figure 1. Testing functionality and expression of GFP-tagged MN1, TEL and MN1-TEL. A. GFP-MN1 stimulates transcription from the MSV
promoter as efficiently as MN1, both in the presence or absence of 1 uM ATRA (24 h incubation) as tested in with a luciferase assay. Western blot
using anti-GFP antibody showing GFP-MN1 protein expression in stably transfected NIH 3T3 cells. GFP-MN1 located to the nucleus, where it was
homogeneously distributed, with notable exception of the nucleoli, where no expression could be detected (left photograph). This expression
pattern did not change upon alpha-amanitin treatment (right photograph). B. TEL and TEL-GFP are equally able to inhibit gene expression from the
MSV promoter. Western blot of a cell lysate of the TEL-GFP-expressing NIH3T3 cell line is stained with anti-GFP and the two isoforms (translation starts
at methionine 1 and 43) of TEL are visible. TEL-GFP is mostly nuclear in NIH3T3 cell lines (left photograph). TEL-GFP-DBDm is located in the cytoplasm
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compared to TEL, which might result in inhibition of TEL
function.
Methods
Fluorescence Recovery After Photobleaching
NIH3T3 cell lines containing the GFP-tagged protein of interest
were seeded on collagen type 1-coated coverslips (BD-Biocoat,
Breda, The Netherlands) 48 h prior to FRAP experiments. Protein
expression was induced 24 h later by adding mifepristone
(Invitrogen) to a final concentration of 0.01 mM. If indicated,
transcription was inhibited by alpha-amanitin (Sigma Aldrich,
50 mg/ml, 3 h prior to FRAP) or stimulated by ATRA (1 mM,
24 h prior to FRAP). Experiments were performed on a Zeiss
LSM 510 Meta confocal microscope (Zeiss, Jena, Germany). GFP
was excited at 488 nm and the emitted fluorescence was detected
in the 505-530 nm range. Nuclei with fluorescence levels
corresponding to physiologically relevant expression levels were
selected for imaging and FRAP at a lateral pixel size of 80 nm. A
region of interest (ROI) of 10 pixels wide and spanning the width
of the nucleus was set up, preferably in the middle of the nucleus.
Thousand scans of 21 ms of the ROI were performed. After 100
scans a bleach pulse of three iterations was given. FRAP data were
normalized to pre-bleach values by subtracting the measured
background and dividing by the average fluorescence intensity of
the 50 points before bleaching again, after subtraction of
background.
FRAP Data Analysis
The model-based analysis of the FRAP data by Monte Carlo
simulation was previously described [15,16,17].Briefly: raw FRAP
curves were normalized to pre-bleach values and the best fitting
curve (by ordinary least squares) was picked from a large set of
computer-generated FRAP curves in which five parameters
representing mobility properties were varied: diffusion rate
(ranging from 0.04 to 25 mm2/s), and two immobile fraction
(ranging from 0–90%), with two different residence times in
immobile state (ranging from 0.1 to 300 s). The size of the ellipsoid
was based on the experimentally-derived average size of the nuclei.
The laser intensity profile used in the simulation of the bleaching
step was derived from confocal image stacks of chemically-fixed
nuclei containing GFP that were exposed to a stationary laser
beam at various intensities and varying exposure times.




To investigate their behaviour in living cells, MN1, TEL and
the oncogenic fusion protein MN1-TEL were tagged with EGFP
and the effect of the tag on their behaviour was tested. GFP-MN1
and GFP-MN1-TEL were able to stimulate transcription of the
MSV promoter at levels similar to their non-GFP tagged versions
(Fig. 1A and C). Since GFP tagged directly to either the C- or N-
terminus of TEL inhibited TEL-function (data not shown), a spacer
was inserted (at the C-terminus) consisting of six glycine-alanine
residues, a strategy we previously applied for other transcription
factors [18]. TEL-s-GFP was able to repress transcription of the
MSV-promoter, similar to wild type TEL (Fig. 1B). The constructs
were stably integrated into NIH3T3 cells using the inducible
GeneSwitch system. Clones with fluorescence intensities corre-
sponding to wild-type levels were selected and Western Blot
analysis showed that the expressed proteins were of the expected
size (Fig. 1A, B and C).
We then performed FRAP experiments to investigate the
behavior of GFP-MN1, GFP-MN1-TEL and TEL-GFP in living
cells. As a control we also determined the mobility of free GFP. As
expected, the GFP protein by itself rapidly recovered to almost
pre-bleach levels (Fig. 2 A, B, and C). TEL-GFP fluorescence
recovered much slower than GFP and did not reach the same final
level (Fig. 2B), suggesting that a considerable fraction of the
protein is immobilised. Quantitative analysis by fitting the
experimental curve to curves generated by Monte Carlo simula-
tion confirmed the presence of a ,20% long-term immobilised
fraction of TEL-GFP, with a characteristic binding time of more
than a minute (Fig. 2B). In the best fitting scenario, mobile TEL
was not completely free but was also involved in very short
immobilisation events in the range of 100 ms or less, 75% being
involved in these interactions at any moment. The function of
TEL in transcription repression, prompted us to examine its
mobility when transcription was inhibited by alpha-amanitin
[19,20]. The immobile fraction of TEL-GFP was largely abolished
after treatment with alpha-amanitin, strongly suggesting that long-
term immobilisation of TEL is due to its involvement in DNA
binding.
GFP-MN1 showed a much slower fluorecence recovery than
free GFP but to a similar level (Fig. 2A). The experimental FRAP
curves were fitted to curves generated by Monte Carlo simulation.
Best fits for GFP-MN1 were obtained with simulated curves
representing a scenario in which the rate constants of immobilisa-
tion and mobilisation are such that ,10% of the protein is
immobile, and individual molecules reside in the immobile state
for on average,10 seconds (1/Koff = 11 s) (Fig. 2A). Since MN1 is
a cofactor for retinoic acid (ATRA)-mediated transcription we
investigated the effect of stimulating the retinoic acid receptor
RAR-RXR. Addition of ATRA lead to a small but reproducible
slow down of fluorescence recovery. Interestingly, the immobile
fraction did not significantly change, but the residence time in the
immobile state was much longer (,30 seconds). In addition, the
fraction involved in short binding events increased. These data
suggest that immobilisation is due to binding to immobile
transcription complexes, where the residence time in RAR-RXR
complexes is longer than in other transcription complexes in which
MN1 may be involved (Meester-Smoor et al., 2008). To further
investigate this, we determined GFP-MN1 mobility after tran-
scription inhibition by alpha-amanitin, similar to the experiments
on TEL mobility. Alpha-amanitin treatment slightly but re-
producibly increased the mobility of GFP-MN1 due to almost
complete loss of the 10% immobile fraction, in agreement with the
hypothesis that immobilisation is due to engagement in transcrip-
tion (Fig. 2A).
(middle photograph). Expression pattern of TEL-GFP upon treatment with 50 ug/ml alpha-amanitin for 3 h (right photograph). Both MN1-TEL and
GFP-MN1-TEL can weakly stimulate transcription from the MSV promoter, while the DNA-binding mutant is a weak repressor. Western blot with anti-
GFP antibody of a lysate of cells expressing GFP-MN1-TEL and GFP-MN1-TEL-DBDm. GFP-MN1-TEL is nuclear, with a tendency to form aggregates
upon higher expression levels (upper two photographs). GFP-MN1-TEL-DBDm is both nuclear and cytoplasmic (left lower photograph). Expression
pattern of GFP-MN1-TEL did not change upon treatment with 50 ug/ml alpha-amanitin for 3 h (right lower photograph).
doi:10.1371/journal.pone.0046085.g001
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Figure 2. FRAP curves and simulation data. A. GFP-MN1 FRAP curves show the fast recovery of MN1 to levels similar as GFP. In the presence of
ATRA the recovery of GFP-MN1 is slightly slower. Alpha-amanitin releases the MN1 protein. Pie diagrams containing simulation data support FRAP
curve data. B. TEL-GFP recovered much slower and leveled off to 70% of pre-bleach values. Simulation data calculated the presence of both a long-
term bound fraction (20%; 59 s) and a short-term bound fraction (57%; 0.63 s). Alpha amanitin released the TEL-GFP protein as shown by FRAP curve
and simulation data. C. GFP-MN1-TEL was largely immobile. A non DNA-binding mutant (DBDm) of GFP-MN1-TEL was mobile and diffused similarly to
GFP-MN1. Alpha-amanitin treatment only partly released MN1-TEL. Simulation data calculated that 10% of the protein remains immobile for a long
period (235 s).
doi:10.1371/journal.pone.0046085.g002
Long-Term DNA Binding by Fusion Protein MN1-TEL
PLOS ONE | www.plosone.org 4 September 2012 | Volume 7 | Issue 9 | e46085
We then applied FRAP to cells expressing the oncogenic fusion
protein GFP-MN1-TEL. FRAP revealed that the fusion protein is
largely immobile (60%), as fluorescence recovered to only ,40%
of pre-bleach levels (Fig. 2C). Quantitative analysis showed 60% of
the GFP-MN1-TEL protein appeared to bind long-term with
a characteristic binding time of ,2 minutes, while another 20% of
the protein was predicted to be involved in binding events of on
average 4 seconds. Transcription inhibition by alpha-amanitin
largely, but not completely abolished the reduced mobility of GFP-
MN1-TEL, suggesting that immobilisation is due to binding to
TEL recognition sites. To further investigate this, we generated
cell lines expressing a non-DNA-binding GFP-MN1-TEL mutant
(GFP-MN1-TEL-DBDm), in which the TEL-DBD was dysfunc-
tional. Behaviour and expression of the GFP-tagged mutant were
identical to that of the non-tagged protein (Fig. 1C). Unlike the
TEL-DBDm, GFP-MN1-TEL-DBDm was largely nuclear. FRAP
analysis revealed that GFP-MN1-TEL-DBDm is mobile (Fig. 2C),
with diffusion rates similar to GFP-MN1. Importantly, these
experiments show that removing the DNA-binding capacity has
a significantly stronger effect than transcription inhibition, most
likely because transcription inhibition does not fully block DNA-
binding of transcription factors, whereas removing the DNA-
binding capacity does. This may explain the more limited effect of
transcription inhibition on TEL and MN1 mobility. Note that,
unfortunately, we were unable to test a TEL non-DNA-binding
mutant (DBDm), because nuclear import and DNA binding of
TEL is dependent on the mutated amino acids, leading to a fully
cytoplasmic localization of TEL-DBDm (Fig. 1B).
We then further investigated the hypothesis that MN1-TEL
binds TEL-recognition sites, thereby suppressing the repressor
function of TEL. The stromelysin promoter is a natural target of
TEL and is frequently used to investigate TEL repression [21].
MN1-TEL was able to stimulate the stromelysin promoter, in
contrast to TEL, which inhibited promoter activity (Fig. 3). This
corroborates the conclusions based on the FRAP experiments
above, that both proteins are competing for the same binding sites
within the promoter. In addition, adding equal amounts of TEL
and MN1-TEL resulted in increased promoter activity, suggesting
that MN1-TEL occupies the majority of the promoters. Thus,
MN1-TEL not only prevents transcription repression by TEL, but
also activates the genes that should be repressed.
Discussion
In this work we investigated the in vivo mobility and DNA-
binding behaviour of MN1, TEL and the leukemogenic fusion
protein MN1-TEL. The relatively high mobility and small
immobilised fraction of MN1 is in concordance with gel filtration
experiments of MN1-expressing cells, in which we noticed that
over 90% of the protein was found in column fractions
corresponding with its monomeric size (unpublished results).
MN1 is a protein that affects RAR/RXR-induced gene expres-
sion. When we added the RAR ligand ATRA to the medium of
cells expressing GFP-MN1, we observed a small decrease in
mobility. Monte Carlo simulation suggests that this corresponds to
a two- to threefold increase in the characteristic DNA-binding
time of the fraction involved in binding events. The remainder of
the protein is either free or involved in very transient binding
events. Blocking transcription by alpha-amanitin released almost
all protein, in accordance with a model where active transcription
is necessary to maintain transcription complexes [22] and with
data obtained with the transcription factor/repair protein TFIIH,
which is also mobilized by alpha-amanitin treatment [23].
Two lines of evidence suggest that immobilisation of TEL and
MN1-TEL is due to DNA binding. Firstly, a non-DNA-binding
mutant of MN1-TEL does not show a significant immobile
fraction. Secondly, the addition of the transcription blocker alpha-
amanitin led to mobilization of the proteins. The only other
transcriptional regulator known to date with an immobile fraction
as profound as that of MN1-TEL is the transcriptional repressor
UTF1, which associates with histones in embryonic stem cells [24].
Other proteins known to be involved in long-term silencing
processes, such as the heterochromatin-associated protein HP-1
and several members of the polycomb complexes, also are partly
immobile, but not to such an extent as MN1-TEL [19,25].
The mobilization of MN1-TEL and TEL upon addition of
alpha-amanitin can be explained in three different ways: first our
observations are surprisingly similar to those of HP-1. For HP-1,
its increased mobility is suggested by the authors to be the
consequence of chromatin decondensation by alpha-amanitin
[26]. This suggests that TEL and MN1-TEL may be involved in
chromatin condensation, well in line with TEL’s role in long-term
repression as proposed by Boccuni et al. [27]. Secondly, it has also
been reported that alpha-aminitin can block chromatin decon-
densation [28], in which case the increased observed mobilities of
TEL and MN1-TEL maybe because their activity is no longer
required, since after prolonged alpha-amanitin exposure, the
majority of chromatin exists in condensed state. Thirdly, since
alpha-amanitin has also been shown to lead to degradation of
RGB1, the largest subunit op RNA Polymerase II [29], it may be
that, irrespective of chromatin state, the mere absence of this most
essential transcription factor leads to decay of existing transcrip-
tion complexes, and prevents formation of new ones. The long
period (24 hours) of alpha amanitin-incubation may then finally
result in a situation where the majority of transcription factors and
related nuclear proteins are mobile, independent from chromatin
status.
Irrespective of which of these explanations is correct (they all
point to a similar model of TEL function and MN1-TEL
dysfunction),it is tempting to the see the long-lasting DNA-
interactions of repressors like TEL and UTF1 in the light of the
distinct timing of transcription initiation and chromatin remodel-
ing suggested previously by Karpova et al. [30]. These authors
provided evidence that the short DNA-interaction times of many
transcription factors generally found with FRAP are those
associated with actual transcription initiation, while the longer,
slower cycling ones found with ChIP (,15 to 90 minutes) reflect
the availability of promoters due to chromatin remodeling rather
than actual binding times of individual factors. In view of this
model it could be speculated that relatively long DNA-binding
times of repressors are related to regulation of the latter process.
The differences in bound fraction suggest that in equilibrium,
more MN1-TEL is bound to TEL-recognition sequences than
TEL when similar amounts of both proteins are present, because
of the longer characteristic binding time of MN1-TEL. Since
MN1-TEL can stimulate gene expression from ETS-responsive
elements, it could thus induce genes that in the normal situation
are inhibited by TEL. Expression of the MN1-TEL fusion protein
is under the control of the MN1 promoter. In the hematopoietic
system, MN1 expression is confined to the granulocyte-monocyte
progenitors (GMP) [10]. TEL expression in these cells has not
been investigated, but is not unlikely since expression of TEL is
wide spread as judged from expression arrays (http://www.
oncomine.org/main/mainx.jsp). It is known that different ETS
proteins can bind to the same promoters [31], therefore it could
also be that MN1-TEL disrupts the function of other proteins from
this family.
Long-Term DNA Binding by Fusion Protein MN1-TEL
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The high affinity of MN1-TEL for DNA could be a consequence
of the loss of domains in TEL involved in regulation of well-timed
release of TEL from the transcription complex. In this regard it is
interesting that MN1-TEL misses the first 54 amino acids of TEL
as it has been shown that the isoform of TEL which lacks the first
42 amino acids is a more active repressor than the isoform starting
at methionine 1 [32]. Sumoylation of lysine 11 in this isoform was
shown to interfere with DNA binding [33]. MN1-TEL lacks this
residue and may therefore display a larger affinity for DNA than
TEL, which is a mixture of both isoforms. Another possibility is
that the MN1 moiety in MN1-TEL enables binding of
coregulators like p300 and RAC3 [8] that may stabilize the
DNA-protein complex and thereby interfere with proper func-
tioning.
Recently, Kawamata et al [34] published FRAP experiments
with the PAX5-TEL fusion protein in which it was shown that this
protein was also immobile. A fusion between PAX5 and the SAM
domain of TEL had similar properties and hence Kawamata et al
attribute the immobility to the dimerization/oligomerization
properties of the SAM domain. However, we think that this
property is not responsible for the immobility of the fusion protein
MN1TEL. Although the SAM domain is present in the MN1-TEL
fusion protein, we were unable to show binding in a immunopre-
cipitation assay between MN1TEL and TEL (Buys et al. [35]) and
also in binding assays using HA-tagged TEL and in vitro
transcribed and translated MN1-TEL and TEL, although TEL
efficiently bound to itself in the same assays (unpublished results).
Moreover, the PAX5 protein contributes its own DNA binding
domain to the fusion protein and hence PAX5-TEL encompasses
the DNA binding domains of both contributing proteins.
In conclusion, our data suggest two possibilities by which the
long-term DNA binding of MN1-TEL may contribute to the
leukemogenic process. The first possibility is that MN1-TEL
competes with TEL for its cognate binding sites and due to its
longer residence time effectively blocks TEL function. This
hypothesis requires that TEL is expressed and is functional in
GMPs. The second possibility is that MN1-TEL blocks access of
other ETS-family members to their cognate binding sites, which
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